Vivo Capital LLC maintained its position in Nabriva Therapeutics AG (NASDAQ:NBRV) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,021,559 shares of the biotechnology company’s stock at the end of the second quarter. Nabriva Therapeutics AG makes up 10.6% of Vivo Capital LLC’s investment portfolio, making the stock its 4th largest position. Vivo Capital LLC owned 147.80% of Nabriva Therapeutics AG worth $42,146,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in NBRV. Renaissance Technologies LLC purchased a new stake in Nabriva Therapeutics AG during the fourth quarter valued at about $103,000. Almanack Investment Partners LLC. purchased a new stake in Nabriva Therapeutics AG during the first quarter valued at about $1,870,000. Nationwide Fund Advisors purchased a new stake in Nabriva Therapeutics AG during the first quarter valued at about $2,074,000. Finally, Wellington Management Group LLP raised its stake in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the period. Institutional investors and hedge funds own 56.65% of the company’s stock.
Shares of Nabriva Therapeutics AG (NBRV) opened at 10.00 on Friday. The company’s 50-day moving average is $10.40 and its 200-day moving average is $10.35. The company’s market cap is $268.38 million. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $12.75.
Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating the Zacks’ consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.34 million. On average, equities analysts predict that Nabriva Therapeutics AG will post ($2.43) EPS for the current year.
NBRV has been the subject of several analyst reports. Cantor Fitzgerald set a $16.00 target price on shares of Nabriva Therapeutics AG and gave the stock a “buy” rating in a report on Thursday, May 11th. HC Wainwright restated a “buy” rating on shares of Nabriva Therapeutics AG in a report on Friday, May 12th. Wedbush restated an “outperform” rating and issued a $13.00 target price on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Saturday, May 27th. Finally, ValuEngine upgraded shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $15.43.
In other news, major shareholder Hbm Healthcare Investments (Ca sold 8,558 shares of the stock in a transaction dated Thursday, June 29th. The shares were sold at an average price of $10.96, for a total transaction of $93,795.68. Following the sale, the insider now owns 2,591,396 shares of the company’s stock, valued at $28,401,700.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George Harrison Talbot sold 325 shares of the stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $100.56, for a total transaction of $32,682.00. Following the sale, the director now directly owns 3,854 shares in the company, valued at approximately $387,558.24. The disclosure for this sale can be found here. Insiders sold 242,708 shares of company stock worth $2,646,784 in the last ninety days.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
What are top analysts saying about Nabriva Therapeutics AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nabriva Therapeutics AG and related companies.